Fig. 4

PI3K/Akt-dependence of the PAK4-mediated cisplatin resistance in cervical cancer cells. a and b: Phosphorylation of PI3K/Akt in Hela (a) and CaSki (b) cells, which were treated with 5 (for Hela cells) or 10 μM (for CaSki cells) cisplatin and with 10 or 20 nM (for Hela cells), or with 15 or 30 nM (for Caski cells), LY294002; c and d: Influence of the treatment with 10 or 20 nM LY294002 in Hela cells, or the treatment with 15 or 30 nM LY294002 in Caski cells on the cisplatin-mediated (5 μM for Hela cells or 10 μM for CaSki cells) viability reduction for 12, 24 or 48 h. Experiments were repeated in triplicate independently. *P < 0.05, **P < 0.01 or ns: no significance